Beacon Harbor Wealth Advisors Inc. lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 2.3% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 71,133 shares of the biopharmaceutical company’s stock after purchasing an additional 1,586 shares during the period. Gilead Sciences comprises 1.7% of […]
Concentrum Wealth Management lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 6.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,766 shares of the biopharmaceutical company’s stock after acquiring an additional 413 shares during the quarter. […]
Gilead Sciences (NASDAQ:GILD – Free Report) had its target price lowered by Royal Bank of Canada from $76.00 to $74.00 in a research note issued to investors on Friday morning, Benzinga reports. The brokerage currently has a sector perform rating on the biopharmaceutical company’s stock. A number of other research analysts also recently issued reports […]
Cozad Asset Management Inc. decreased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 4.4% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 69,658 shares of the biopharmaceutical company’s stock after selling 3,185 shares during the period. Cozad Asset Management Inc.’s holdings […]
Cozad Asset Management Inc. cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 4.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 69,658 shares of the biopharmaceutical company’s stock after selling 3,185 shares during […]